Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Thomas M. Jahn"'
Autor:
Zev Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Seung Tae Kim, Joseph Chao, Daniel Catenacci, Sung Yong Oh, Heloisa P. Soares, J. Eva Selfridge, Yongjun Cha, Roland T. Skeel, Hyung-Don Kim, Anh Tran, Achim Moesta, Tracy Dela Cruz, Anil Singhal, Thomas M. Jahn, Farshid Dayyani
Publikováno v:
Cancer Research. 82:CT015-CT015
Background: The ecto-ATPase CD39 is the rate-limiting enzyme in the adenosine pathway that plays an important immune regulatory role. Preclinically, inhibition of CD39 by TTX-030, a first-in-class fully human anti-CD39 antibody, reversed immunosuppre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5b26898f67f9e8d47a26563d047b764
https://doi.org/10.1158/1538-7445.am2022-ct015
https://doi.org/10.1158/1538-7445.am2022-ct015
Autor:
Richard R. Furman, Sven De Vos, John P. Leonard, Jacqueline C. Barrientos, Marshall T. Schreeder, Ian W. Flinn, Jeff P. Sharman, Thomas Boyd, Nathan Fowler, Kanti R. Rai, Yeonhee Kim, Leanne M. Holes, Roger Dansey, Thomas M. Jahn, Steven E. Coutre
Publikováno v:
Blood. 122:4180-4180
Introduction PI3Kδ signaling is critical for the proliferation and survival as well as for homing and tissue retention of malignant B cells. Idelalisib is a first-in-class, targeted, highly selective, oral inhibitor of PI3Kδ that has shown consider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e1c887c49d1b6fa42dbafc936467d8f
https://doi.org/10.1182/blood.v122.21.4180.4180
https://doi.org/10.1182/blood.v122.21.4180.4180
Publikováno v:
2006 6th World Congress on Intelligent Control & Automation; 2006, p8196-8200, 5p
Publikováno v:
2006 1ST IEEE Conference on Industrial Electronics & Applications; 2006, p1-6, 6p
Autor:
Bertrand Coiffier, Peter Hillmen, Ian W. Flinn, Andrew R. Pettitt, Bruce D. Cheson, Nicole Lamanna, Paolo Ghia, Richard R. Furman, Michael Hallek, Susan O'Brien, Herbert Eradat, Thomas J. Ervin, Jeff P. Sharman, Xiaoming Li, Jacqueline C. Barrientos, Thomas Jahn, Andrew D. Zelenetz, Steven Coutre, John M. Pagel, Thomas J. Kipps
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:S201-S202
302 Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia John M. Pagel, Steven E. Coutre, Richard R. Furman, Jeff P. Sharman, Bruce D. Cheson, Peter Hillmen, Jacqueline C. Barrientos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22af917ec2c4a4d2d54781f872edaaac
https://doi.org/10.1016/j.clml.2015.04.062
https://doi.org/10.1016/j.clml.2015.04.062